Quick Takeaways
- ASTRAZENECA PLC filed SCHEDULE 13D/A for Cellectis S.A. Ordinary shares, nominal value of EUR0.05 per ordinary share (CLLS).
- Disclosed ownership: 44%.
- Date of event: 23 Jan 2025.
ASTRAZENECA PLC - 23 Jan 2025 SCHEDULE 13D/A Report for Cellectis S.A. Ordinary shares, nominal value of EUR0.05 per ordinary share (CLLS)
- Filing Manager
- ASTRAZENECA PLC
- Reporting Manager
- AstraZeneca PLC
- Symbol
- CLLS
- Shares outstanding
- 100,000,000 shares
- Disclosed Ownership
- 44,000,000 shares
- Ownership
- 44%
- Form type
- SCHEDULE 13D/A
- Filing time
- 24 Jan 2025, 09:52:01 UTC
- Date of event
- 23 Jan 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ASTRAZENECA PLC disclosed 44% ownership in Cellectis S.A. Ordinary shares, nominal value of EUR0.05 per ordinary share (CLLS) on 23 Jan 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 24 Jan 2025, 09:52.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| AstraZeneca PLC | 44% | 44,000,000 | 44,000,000 | 0 | /s/ Adrian Kemp | Adrian Kemp, Company Secretary | 0000901832 |
| AstraZeneca Holdings B.V. | 44% | 44,000,000 | 44,000,000 | 0 | /s/ Kamila Kozikowska | Kamila Kozikowska, Director |